3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
3
Melanoma
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Anus Neoplasms
1
Interventions
Fluorouracil
14
Radiotherapy
11
Mitomycin
9
Radiation
8
Capecitabine
8
Surveys and Questionnaires
6
Drug Therapy
6
Cisplatin
6
pembrolizumab
5
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Irinotecan
3
Immune Checkpoint Inhibitors
3
Cetuximab
3
Carboplatin
3
Biopsy
3
tislelizumab
2
durvalumab
2
atezolizumab
2
aldesleukin
2
Therapeutics
2
Specimen Handling
2
Papillomavirus Vaccines
2
Oxaliplatin
2
Observation
2
Nivolumab
2
Cyclophosphamide
2
Blood Specimen Collection
2
Adoptive Transfer
2
toripalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Anus Neoplasms
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled